Dedipya Bhamidipati
@drdedipya
Followers
89
Following
302
Media
13
Statuses
56
Internal Medicine Chief Resident @sunydownstate/Brooklyn VA | 2025-26 Heme-Onc applicant AAMC ID: 15373622
Joined August 2023
Please check out this review of Emerging Tumor Agnostic Biomarkers! .Grateful to have had @AliSchram as a mentor. I learned a lot from her insights as a PI on numerous clinical trials in the Early Drug Development clinic @MSKCancerCenter!.
Featured today by @MSKLibrary: Emerging Tumor-Agnostic Molecular Targets.#CancerResearch #TumorAgnosticTherapies.#PrecisionMedicine #MolecularTargets.#TargetedTherapies #OncologyBreakthroughs.#FutureOfCancerCare #InnovativeMedicine.#EmergingTherapies #CancerAwareness
0
0
3
RT @drdedipya: @hsafaMD Excited to be applying to #HemeOnc fellowship this cycle!. I’m Dedipya Bhamidipati—IM chief resident! . Excited to….
0
3
0
RT @DrYukselUrun: BREAKING from @NEJM .In cancer patients w/ Cancer-Associated Venous Thromboembolism, reduced-dose apixaban (2.5 mg BID) i….
0
390
0
De-escalation of ICI therapy in NSCLC through either a) lower dosing regiments, b) decreased frequency of administration or c) fixed duration of therapy. The economic benefits would revolutionize antibody use! Such a valuable read @JordiRemon and @BenjaminBesseMD!
1
0
2
Establishing nivo/AVD in elderly patients with classic Hodgkin’s lymphoma would transform the care of patients suffering from cHL above the age of 60 years! Congratulations @PallawiTorkaMD @PaolaGhione_MD @SantoshVardhana!! So blessed to have worked with you!
0
2
6
Learned a lot from Dr. Salles during my elective in Lymphoma clinics over the past month. I got to see very interesting patients, with even more exciting treatment plans! @MSKCancerCenter truly harbors the most insightful teachers. Thankful to @Efrat_Luttwak for this rotation!!!
0
1
16
RT @AliSchram: Now available on pubmed! Results of the zenocutuzumab (Bizengri) basket trial in NRG1 fusion + solid tumors. This trial led….
pubmed.ncbi.nlm.nih.gov
Zenocutuzumab showed efficacy in patients with advanced NRG1 fusion-positive cancer, notably NSCLC and pancreatic cancer, with mainly low-grade adverse events. (Funded by Merus; eNRGy ClinicalTrial...
0
1
0
When you’re watching your Lymphoma attending casually drop ASH updates during your heme elective at the VA! Perfect timing!
Thank you @OncBrothers @TargetedOnc for the opportunity to share my thoughts. We discuss high impact #lymphoma abstracts from #ASH24 @ASH_hematology and my take on how they impact care of patients with lymphoma. Do give a listen. #lymsm @MSKCancerCenter @MSK_DeptOfMed.
0
0
1
RT @BalazsHalmosMD: Cancer statistics- 2025.👀.Some 🫁 cancer observations:.1. Continued nice decrease in LC incidence/death rates.2. BUT pro….
0
30
0
RT @DrYukselUrun: Adjuvant IO trials in muscle-invasive urothelial carcinoma:.IMvigor010: Atezo DFS HR 0.89, OS HR 0.85. CheckMate 274: Niv….
0
45
0
RT @PTarantinoMD: ADCs are among the most rapidly expanding treatment modalities in oncology, with 11 ADCs approved and >200 in active deve….
0
69
0
0
71
0
RT @DrYukselUrun: TROPHY-U-01 Cohort 2: .Sacituzumab Govitecan achieved an ORR of 32% in cisplatin-ineligible metastatic urothelial cancer.….
0
22
0
RT @JAMAOnc: Radiation therapy followed by intrathecal trastuzumab and pertuzumab for HER2+ breast leptomeningeal disease is safe with init….
0
46
0
RT @UGrewalMD: It truly breaks my heart to see patients in my clinic who come to the office hoping for a “cure” when there isn’t one. I kno….
0
3
0
Fun fact to share from this rotation which I was unaware of: filgrastim/peg-filgrastim should not be used in patients with sickle cell disease (consideration came up for neutropenic fever in this case), as it serves as another form of stressor which can precipitate pain crisis!.
0
0
0
Loving every second of the 2nd week of inpatient lymphoma rotation at @MSKCancerCenter. Learning so much, and seeing such rare pathologies has been so enlightening. And all the TLS monitoring too 🤣.
0
0
2
RT @OncoAlert: Just Out on @TheLancetOncol. The AtTEnd trial :A multicentre, double-blind, phase 3 study investigating the addition of atez….
0
24
0